NEW YORK (Fortune)—When it comes to stem cells, the public—and the media—tend to focus on embryos. But researchers and analysts say marketable therapies already are emerging from less controversial work with adult stem cells.
Adult cells make up the lion’s share of the stem cell space, mainly because they are easier to come by than embryonic cells, and less expensive to run in clinical trials. They are also derived from mature tissue, like bone marrow or umbilical cord blood, so they avoid the ethical debate that surrounds embryonic stem cells.
Posted by Natalie Higle at 08:58 PM. Filed under: News •
